Dr. G. Paul Evans Named President and CEO
Durham, N.C. — February 5, 2019 – Velocity Clinical Research, a clinical trials site organization focused on setting a new bar for providing rapid data delivery with the highest level of patient care, has announced it has acquired its first three research sites in the USA. The company acquired Clinical Research Institute of Southern Oregon (CRISOR) of Medford, Oregon and New Horizons Clinical Research (NHCR) of Cincinnati, Ohio in an earlier single transaction. In December 2018 the company also acquired MD Clinical of Hallandale Beach, Florida. Velocity investigator sites have 20+ years of clinical trial experience and over 1700 completed studies across a broad range of therapeutic areas.
At the same time the company announced that Dr. G. Paul Evans has been named President and Chief Executive Officer. Paul joins the company after 26 years of “perfect symmetry” in the site business: 13 years running sites and 13 years managing them from the sponsor/CRO side. He has served as Corporate VP, Global Site Solutions at PAREXEL; Vice President, Global Site Management at IQVIA; and was a founder and Managing Director of Synexus, a global site organization.
“After a quarter of a century in this industry patient recruitment is still the biggest problem in clinical trials. Much is changing in the sites business, which is why I came back into the space at this time and I want Velocity to set a new industry standard for delivering high-quality study data as quickly and efficiently as possible.”
Paul made the move from the UK to the U.S. for an irresistible opportunity: to set new standards in clinical research. “Velocity is in an enviable position. Our sites bring different strengths to the company, and all set industry standards in their delivery of high-quality data and patient care. The patient recruitment model is changing; old recruitment methods are failing. Nearly 30% of investigator sites in the U.S. fail to enroll a patient. By managing patient recruitment with surgical precision and focusing on the patient we are positioning Velocity to be the industry leader in setting – and surpassing – sponsor expectations.”
Regarding its most recent acquisition, Dr. Evans stated that “Dr. Safirstein and MD Clinical bring everything we are looking for in a site: impeccable clinical research practices, a robust trial pipeline, and great relationships with their patients. We are thrilled to have them aboard.” The company is planning for growth and is actively seeking experienced investigative sites that meet its high standard for quality data and patient care.
About Velocity Clinical Research
Velocity Clinical Research, headquartered in Durham, N.C, is a leading site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. With over 20 years of experience and more than 1700 studies completed Velocity sites have refined their patient recruitment strategies while maintaining a focus on delivering timely and reliable data quality while placing the care of the patient at the heart of everything they do.
For more information visit our web site at https://velocityclinical.comSource: Velocity Clinical